Symbio To Start Rigosertib Phase I In Japan
This article was originally published in PharmAsia News
Executive Summary
Symbio Pharmaceutical Ltd gears up to commence Phase I clinical trials for rigosertib injection in Japan for myelodysplastic syndrome.